Anne L Fuhlbrigge1, Thomas Bengtsson2, Stefan Peterson2, Alexandra Jauhiainen3, Göran Eriksson4, Carla A Da Silva3, Anthony Johnson3, Tariq Sethi3, Nicholas Locantore5, Ruth Tal-Singer5, Malin Fagerås6. 1. Pulmonary Sciences and Critical Care, Department of Medicine, University of Colorado School of Medicine, Denver, CO, USA. 2. StatMind Statistical and Mathematical Modelling, Innovation and Design AB, Lund, Sweden. 3. AstraZeneca, Research and Development, Early Clinical Development, Gothenburg, Sweden. 4. Department of Respiratory Medicine and Allergology, Lund University Hospital, Lund, Sweden. 5. GlaxoSmithKline Research and Development, King of Prussia, PA, USA. 6. Global Product and Portfolio Strategy, Global Medical Affairs, Gothenburg, Sweden. Electronic address: malin.fageras@astrazeneca.com.
Abstract
BACKGROUND: Occurrence of severe asthma exacerbations are the cornerstone of the evaluation of asthma management, but severe asthma exacerbations are rare events. Therefore, trials that assess drug efficacy on exacerbations are done late in clinical development programmes. We aimed to establish an endpoint capturing clinically relevant deteriorations (diary events) that, when combined with severe exacerbations, create a composite outcome (CompEx). CompEx needs to strongly mirror results seen with the severe exacerbation-validated outcome, to allow the design of clinical trials of shorter duration and that include fewer patients than trials assessing severe exacerbations. METHODS: Data from 12 asthma trials of 6 months or 12 months duration and, with standardised collection of exacerbations and diary card variables, were used to construct and test CompEx. The study populations had a mean age of 35-53 years, 59-69% were female, and had a mean FEV1 percentage of predicted normal of 63-84%. With data from five trials, we established a series of diary events based on peak expiratory flow (P), reliever use (R), symptoms (S), awakenings (A), and threshold values for change from baseline and slopes to assess trends. For the development phase, we evaluated different variable combinations and deterioration criteria to select the most robust algorithm to define a diary event for the composite outcome. We defined a composite outcome, CompEx, as first occurrence of a diary event or a severe exacerbation. We assessed the performance of CompEx in seven trials by comparing the event frequency, treatment effect (hazard ratio; HR), and the sample size needed for future trials for the CompEx versus episodes of severe exacerbations. FINDINGS: CompEx (based on PRS) was the algorithm that best fulfilled our two-set criteria. When censored at 3 months, CompEx resulted in 2·8 times more events than severe exacerbations, and while preserving the treatment effect observed on severe exacerbations (CompEx over severe exacerbation average HR 1·01). The increased number of events, together with the sustained treatment effect, resulted in a large net gain in power, with a 67% mean reduction in the number of patients required in a drug trial for severe exacerbations. In six of seven comparisons tested, CompEx reduced the sample size needed by at least 50%. Validation of independent test populations confirmed the ability of CompEx to increase event frequencies, preserve treatment effect, and reduce the number of patients needed. INTERPRETATION: CompEx is a composite outcome for evaluation of new asthma therapies. CompEx allows design of shorter trials that require fewer patients than studies of severe exacerbations, while preserving the ability to show a treatment effect compared with severe exacerbations. FUNDING: AstraZeneca.
RCT Entities:
BACKGROUND: Occurrence of severe asthma exacerbations are the cornerstone of the evaluation of asthma management, but severe asthma exacerbations are rare events. Therefore, trials that assess drug efficacy on exacerbations are done late in clinical development programmes. We aimed to establish an endpoint capturing clinically relevant deteriorations (diary events) that, when combined with severe exacerbations, create a composite outcome (CompEx). CompEx needs to strongly mirror results seen with the severe exacerbation-validated outcome, to allow the design of clinical trials of shorter duration and that include fewer patients than trials assessing severe exacerbations. METHODS: Data from 12 asthma trials of 6 months or 12 months duration and, with standardised collection of exacerbations and diary card variables, were used to construct and test CompEx. The study populations had a mean age of 35-53 years, 59-69% were female, and had a mean FEV1 percentage of predicted normal of 63-84%. With data from five trials, we established a series of diary events based on peak expiratory flow (P), reliever use (R), symptoms (S), awakenings (A), and threshold values for change from baseline and slopes to assess trends. For the development phase, we evaluated different variable combinations and deterioration criteria to select the most robust algorithm to define a diary event for the composite outcome. We defined a composite outcome, CompEx, as first occurrence of a diary event or a severe exacerbation. We assessed the performance of CompEx in seven trials by comparing the event frequency, treatment effect (hazard ratio; HR), and the sample size needed for future trials for the CompEx versus episodes of severe exacerbations. FINDINGS: CompEx (based on PRS) was the algorithm that best fulfilled our two-set criteria. When censored at 3 months, CompEx resulted in 2·8 times more events than severe exacerbations, and while preserving the treatment effect observed on severe exacerbations (CompEx over severe exacerbation average HR 1·01). The increased number of events, together with the sustained treatment effect, resulted in a large net gain in power, with a 67% mean reduction in the number of patients required in a drug trial for severe exacerbations. In six of seven comparisons tested, CompEx reduced the sample size needed by at least 50%. Validation of independent test populations confirmed the ability of CompEx to increase event frequencies, preserve treatment effect, and reduce the number of patients needed. INTERPRETATION: CompEx is a composite outcome for evaluation of new asthma therapies. CompEx allows design of shorter trials that require fewer patients than studies of severe exacerbations, while preserving the ability to show a treatment effect compared with severe exacerbations. FUNDING: AstraZeneca.
Authors: Salman Siddiqui; Loren C Denlinger; Stephen J Fowler; Praveen Akuthota; Dominick E Shaw; Liam G Heaney; Louise Brown; Mario Castro; Tonya A Winders; Monica Kraft; Scott Wagers; Michael C Peters; Ian D Pavord; Samantha Walker; Nizar N Jarjour Journal: Am J Respir Crit Care Med Date: 2019-04-01 Impact factor: 21.405
Authors: Steve N Georas; Rosalind J Wright; Anastasia Ivanova; Elliot Israel; Lisa M LaVange; Praveen Akuthota; Tara F Carr; Loren C Denlinger; Merritt L Fajt; Rajesh Kumar; Wanda K O'Neal; Wanda Phipatanakul; Stanley J Szefler; Mark A Aronica; Leonard B Bacharier; Allison J Burbank; Mario Castro; Laura Crotty Alexander; Julie Bamdad; Juan Carlos Cardet; Suzy A A Comhair; Ronina A Covar; Emily A DiMango; Kim Erwin; Serpil C Erzurum; John V Fahy; Jonathan M Gaffin; Benjamin Gaston; Lynn B Gerald; Eric A Hoffman; Fernando Holguin; Daniel J Jackson; John James; Nizar N Jarjour; Nicholas J Kenyon; Sumita Khatri; John P Kirwan; Monica Kraft; Jerry A Krishnan; Andrew H Liu; Mark C Liu; M Alison Marquis; Fernando Martinez; Jacob Mey; Wendy C Moore; James N Moy; Victor E Ortega; David B Peden; Emily Pennington; Michael C Peters; Kristie Ross; Maria Sanchez; Lewis J Smith; Ronald L Sorkness; Michael E Wechsler; Sally E Wenzel; Steven R White; Joe Zein; Amir A Zeki; Patricia Noel Journal: J Allergy Clin Immunol Date: 2021-11-29 Impact factor: 14.290
Authors: Alexandra Jauhiainen; Lieke E J M Scheepers; Anne L Fuhlbrigge; Tim Harrison; James Zangrilli; Esther Garcia Gil; Per Gustafson; Malin Fagerås; Carla A Da Silva Journal: ERJ Open Res Date: 2020-10-19
Authors: Anastasia Ivanova; Elliot Israel; Lisa M LaVange; Michael C Peters; Loren C Denlinger; Wendy C Moore; Leonard B Bacharier; M Alison Marquis; Nathan M Gotman; Michael R Kosorok; Chalmer Tomlinson; David T Mauger; Steve N Georas; Rosalind J Wright; Patricia Noel; Gary L Rosner; Praveen Akuthota; Dean Billheimer; Eugene R Bleecker; Juan Carlos Cardet; Mario Castro; Emily A DiMango; Serpil C Erzurum; John V Fahy; Merritt L Fajt; Benjamin M Gaston; Fernando Holguin; Sonia Jain; Nicholas J Kenyon; Jerry A Krishnan; Monica Kraft; Rajesh Kumar; Mark C Liu; Ngoc P Ly; James N Moy; Wanda Phipatanakul; Kristie Ross; Lewis J Smith; Stanley J Szefler; W Gerald Teague; Michael E Wechsler; Sally E Wenzel; Steven R White Journal: J Biopharm Stat Date: 2020-09-17 Impact factor: 1.051
Authors: Elliot Israel; Loren C Denlinger; Leonard B Bacharier; Lisa M LaVange; Wendy C Moore; Michael C Peters; Steve N Georas; Rosalind J Wright; David T Mauger; Patricia Noel; Praveen Akuthota; Julia Bach; Eugene R Bleecker; Juan Carlos Cardet; Tara F Carr; Mario Castro; Angeles Cinelli; Suzy A A Comhair; Ronina A Covar; Laura Crotty Alexander; Emily A DiMango; Serpil C Erzurum; John V Fahy; Merritt L Fajt; Benjamin M Gaston; Eric A Hoffman; Fernando Holguin; Daniel J Jackson; Sonia Jain; Nizar N Jarjour; Yuan Ji; Nicholas J Kenyon; Michael R Kosorok; Monica Kraft; Jerry A Krishnan; Rajesh Kumar; Andrew H Liu; Mark C Liu; Ngoc P Ly; M Alison Marquis; Fernando D Martinez; James N Moy; Wanda K O'Neal; Victor E Ortega; David B Peden; Wanda Phipatanakul; Kristie Ross; Lewis J Smith; Stanley J Szefler; W Gerald Teague; Abigail F Tulchinsky; Pandurangan Vijayanand; Michael E Wechsler; Sally E Wenzel; Steven R White; Amir A Zeki; Anastasia Ivanova Journal: J Allergy Clin Immunol Date: 2021-03-02 Impact factor: 14.290
Authors: Tim Harrison; Ian D Pavord; James D Chalmers; Glenn Whelan; Malin Fagerås; Annika Rutgersson; Laura Belton; Shahid Siddiqui; Per Gustafson Journal: ERJ Open Res Date: 2020-06-08
Authors: Christopher McCrae; Marita Olsson; Per Gustafson; Anna Malmgren; Malin Aurell; Malin Fagerås; Carla A Da Silva; Anders Cavallin; Jonathan Paraskos; Karin Karlsson; Cecilia Wingren; Phillip Monk; Richard Marsden; Tim Harrison Journal: Clin Exp Allergy Date: 2020-11-03 Impact factor: 5.018